SEP 10, 2026 · PHASE 2 TRIAL
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
ClinicalTrials.gov
This is a Phase 2 clinical trial registry record with no reported results; it describes a planned study of tucatinib combination therapy in heavily pretreated HER2+ breast cancer.
Reported
Planned enrollment66
Study phasePhase 2
Primary outcome measureConfirmed Objective Response Rate (cORR) pe…